SEC Form 4 · accession 0001209191-17-063711
Regulus Therapeutics Inc. · RGLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy Michael Wright
Officer — Chief R & D Officer
Period of report
Dec 4, 2017
Accepted (ET)
Dec 5, 2017 · 9:31 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001505512
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.30 | Dec 4, 2017 | A | 100,000 | A | Dec 4, 2017 | Oct 2, 2026 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1On October 3, 2016, the reporting person was granted an option to purchase 400,000 shares of common stock. The option vests in increments of 100,000 shares upon the achievement of certain performance criteria. On December 4, 2017, the performance criteria for the first goal were met, resulting in the vesting of 100,000 shares.